Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Should l Buy ?
Source: Globenewswire
Cognition Therapeutics' START Study Progress: Cognition Therapeutics has announced that its Phase 2 'START' Study for the treatment of early Alzheimer's disease has surpassed 50% enrollment, supported by a grant from the National Institute of Aging. The study aims to evaluate the efficacy of zervimesine (CT1812) in individuals with mild cognitive impairment.
Potential Benefits of Zervimesine: Preliminary results from previous studies suggest that zervimesine may significantly slow cognitive decline in patients with lower levels of the protein p-tau217, indicating a promising treatment response for those in the early stages of Alzheimer's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
